Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir

Journal of Infectious Diseases

Volumn 212, Issue 2, 2015, Pages 258-263

  Sung, Julia A ^a   Lam, Sharon ^c   Garrido, Carolina ^a   Archin, Nancie ^a   Rooney, Cliona M ^c   Bollard, Catherine M ^d   Margolis, David M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

adoptive T cell therapy; ex vivo expanded T cells; HIV cure; HIV eradication; HIV immunology; HIV T cells; latent reservoir; vorinostat

Indexed keywords

ANTIRETROVIRUS AGENT; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HYDROXAMIC ACID;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE CARRIER; ERADICATION THERAPY; EX VIVO STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LATENT VIRUS INFECTION; PRIORITY JOURNAL; VIRUS INHIBITION; CELL CULTURE; COCULTURE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; VIROLOGY;

ANTI-HIV AGENTS; CELLS, CULTURED; COCULTURE TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84936874205     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv022     Document Type: Conference Paper

References (14)

1. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1: 1284-90.
2. Barton KM, Burch BD, Soriano-Sarabia N, Margolis DM. Prospects for treatment of latent HIV. Clin Pharmacol Ther 2013; 93: 46-56.
3. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501.
4. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-6.
5. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014; 32: 798-808.
6. Lam S, Bollard C. T-cell therapies for HIV. Immunotherapy 2013; 5: 407-14.
7. Chapuis AG, Casper C, Kuntz S, et al. HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood 2011; 117: 5391-402.
8. Lam S, Sung J, Cruz C, et al. Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: Implications for immunotherapy. Mol Ther 2014; doi: 10.1038/mt.2014.207.
9. Archin NM, Eron JJ, Palmer S, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008; 22: 1131-5.
10. Yang H, Wu H, Hancock G, et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis 2012; 206: 552-61.
11. Papuchon J, Pinson P, Lazaro E, et al. Resistance mutations and CTL epitopes in archived HIV-1 DNA of patients on antiviral treatment: toward a new concept of vaccine. PLOS One 2013; 8: e69029.
12. Buckheit RW 3rd, Siliciano RF, Blankson JN. Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells. Retrovirology 2013; 10: 68.
13. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482-5.
14. Jones RB, O'Connor R, Mueller S, et al. Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic TLymphocytes. PLOS Pathog 2014; 10: e1004287.